Pharmaron (03759) announced its projected financial performance for the first half of 2025. The group expects revenue to reach approximately RMB6.33 billion to RMB6.50 billion, representing a 13% to 16% year-on-year increase. However, net profit attributable to shareholders is anticipated to decline significantly to between RMB679 million and RMB713 million, marking a 36% to 39% decrease compared to the same period last year.

Core net profit, which excludes non-recurring items, is forecasted at RMB624 million to RMB648 million, reflecting robust growth of 34% to 39% year-on-year. Adjusted non-IFRS net profit attributable to shareholders is projected to rise by 6% to 11%.

Based on mid-range estimates for the second quarter of 2025, the company anticipates a 13.11% year-on-year revenue increase. Core net profit is expected to grow by 23.33%, while adjusted non-IFRS net profit shows a 13.67% rise.

The company attributed the decline in net profit primarily to reduced non-recurring items, despite sustained improvement in core business operations.